MAPK1 and cancer: Hence, suppression of ERK by BITC + CA might be the essential finding in this study as this quality has stimulated intensive efforts by the pharmaceutical industry and research community to develop novel inhibitors that specifically block and inactivate ERK protein for cancer treatment (Roberts and Der 2007).